part seroquel depression anxiety astrazeneca slowly rolling pr seroquel treatment depression generalized anxiety disorder something called th international forum mood anxiety disorders astrazeneca via academic frontman stuart montgomery trotted data latest clinical trials purportedly show seroquel beat placebo depression gad quote detached independent non conflicted academic author stuart montgomery dr stuart montgomery imperial college school medicine university london author depression monotherapy study said study results remarkable doses seroquel xr examined provided improvements mdd gad symptoms results studies still ongoing add understanding seroquel xr conditions remarkable 'quell slight advantage placebo independent academic psychiatrist willing pimp seroquel blatantly would appear dr montgomery aware putting butter bread finding modest perhaps moderate advantage drug placebo treating depression anxiety far remarkable given dozens drugs psychotherapies demonstrated similar better efficacy remarkable seroquel related increased risk diabetes likely case competing depression treatments course since movement started treat depression antipsychotics perhaps see many people depression moving toward increased risk diabetes might worth noting madrs measure depression reported press release one question regarding eating eat better score antipsychotic linked weight gain set well eat lot score better item taken sign less depressed i tracking seroquel everything bandwagon time i ca wait see headed next part academic salesperson krusty klown might say i heartily endorse event product stuart montgomery quotes press releases agomelatine agomelatine interesting potentially valuable antidepressant effective moderate severe depression says professor stuart montgomery imperial college school medicine london new agent unique mode action improves sleep without affecting daytime alertness efficacy compromised sexual side effects tolerability problems discontinuation symptoms escitalopram lexapro results important show treatment disposal effective without sacrificing good side effect profile obviously preferred patients commented study author professor stuart montgomery imperial college school medicine london united kingdom ideal combination first line treatment good efficacy good tolerability study shows escitalopram potency non selective snris combined good tolerability conventional ssris concluded lexapro consistent advantage really came surprise marvelled prof montgomery shocking data one expecting added stage already knew something special drug finally prof montgomery mentioned results coming studies referred staggering decisive establishing lexapro long term effectiveness treating gad sad one piece dr montgomery may interest readers via guardian leading figure world psychiatry gave pharmaceutical company advice get new drug approved sitting committee deciding licence application internal memorandum pfizer world largest drug company says stuart montgomery would happy become paid adviser declare interest committee safety medicines csm drug antidepressant rival prozac licensing process read whole article see think dr montgomery key opinion leaders similar conflicts interest speak supposed view independent expert researchers whose enthusiastic product endorsements based purely based science manner every drug company trot eager academic spokespeople sign academic medicine become rotten core